TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02329431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: activation curriculum
Description: psychosocial activation curriculum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: support group
Description: parent directed support group
Study: NCT01940562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children \< 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets.
Study: NCT01018511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tamsulosin hydrochloride OCAS 0.4 mg
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tamsulosin hydrochloride OCAS 0.4 mg
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tamsulosin hydrochloride OCAS 0.4 mg
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg
Description: tablet
Study: NCT02456987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Gear
Description: Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
Study: NCT01018511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg
Description: tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamsulosin hydrochloride OCAS 0.4 mg
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
Description: tablet
Study: NCT01021930

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
Description: Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
Description: Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
Study: NCT01447914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study: NCT01843465

Intervention type: OTHER
Intervention: Maneuvers for documenting the disconnection
Study: NCT00967369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Given IV
Study: NCT00826761

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: One capsule per meal test (high dose or low dose)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: One capsule per meal test (high dose or low dose)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsuel every morning
Study: NCT03342924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flanker Test and physical fitness test
Description: Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
Study: NCT02706054

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: The patients received an IM injection of saline near the nerve root (periradicular)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: The patients received an IM injection of meloxicam near the nerve root (periradicular)
Study: NCT02251041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antithrombin-III

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apotransferrin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human recombinant erythropoietin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutathione

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfa-tocopherol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoprostenol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride solution
Study: NCT03819920

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk Assessment (CCRAT)
Description: Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Patients receive standardized general information about colorectal cancer screening over the telephone.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care (UC)
Description: Patients receive standardized general information about colorectal cancer screening over the telephone.
Study: NCT01737541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03723837

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Polio Vaccine (IPV)
Description: Children receive one or two doses of IPV based on study arm they fall in

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Polio Vaccine (IPV)
Description: Children receive one or two doses of IPV based on study arm they fall in
Study: NCT03738787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreatic duct occlusion with Neoprene
Description: Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreato-Jejunal anastomosis
Description: Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
Study: NCT03677908

Intervention type: OTHER
Intervention: ElectroEncephaloGraphy
Description: Density ElectroEncephaloGraphy analysis

Intervention type: OTHER
Intervention: ElectroEncephaloGraphy
Description: Density ElectroEncephaloGraphy analysis
Study: NCT00331162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: 30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin
Description: 1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr \< 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature \> 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours
Study: NCT01728740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose/Metformin FDC (BAY81-9783)
Description: Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
Study: NCT03109015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
Study: NCT03116282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-alcohol therapy
Description: Conversational therapy sessions provided via video conference by a professional alcohol therapist.
Study: NCT04221035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2 (max dose 2 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 750 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 175 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: 3 mg/m2/day (max dose 6 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 200 mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 1500 mg/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 30 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: \< 9kg: 1.0 mg/kg/dose 9 kg to \< 16 kg : 1.2 mg/kg/dose 16 kg to 23 kg : 1.1 mg/kg/dose \>23 kg to 34 kg: 0.95 mg/kg/dose \>34 kg: 0.8 mg/kg/dose Infusion IV over 2 hours Administration every 6 hours for a total of 16 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m2/dose IV short infusion (15'), at least 24 h after the last busulfan dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 300 mg/m2/day over 2 hours

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 21.6 Gy 21.6 Gy + boost de 14.4 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: Patients \>12 kg are dosed based on the BSA: 10 mg/m\^2/day Patients ≤ 12 kg are dosed according to their body weight: 0.33 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2/24h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 100 MG
Description: 100 mg/m²/Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50 mg/m²/jour de J0 à J4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Cyclophosphamide has been demonstrated to have a cytostatic effect in many tumour types. The active metabolites of cyclophosphamide are alkylating agents which transfer alkyl groups to DNA during the process of cell division, thus preventing normal synthesis of DNA.
Study: NCT03591289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NMB with rocuronium bromide
Description: Moderate versus deep neuromuscular block Not a device study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NMB with rocuronium bromide
Description: Moderate versus deep neuromuscular block Not a device study
Study: NCT04327037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded Haploidentical Natural Killer cells
Description: One dose (from 20x to \>100x 10\^6 /kg) of expanded haploidentical NK cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 6 doses of IL-2 (1 × 10\^6 units/m2) from -1 day every other day.
Study: NCT02283645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 % minoxidil lotion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04572295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: E7090 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: E7090 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Description: E7090 oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane oral tablet.
Study: NCT01303861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
Study: NCT02819193

Intervention type: OTHER
Intervention: raw mother's own milk
Description: Infants receive mother's own milk before day 7.
Study: NCT01303861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Nicotine Replacement Therapy Groups:~1. For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~2. For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~1. For smokers with high baseline CO: 42 mg/24 h for 1 week~2. For smokers with low baseline CO: 21 mg/24 h for 1 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Inhaler
Description: Nicotine inhaler to use as needed after quit date
Study: NCT00659360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given orally
Study: NCT00124982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Description: During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Description: During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
Description: During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tumor Necrosing Factor (TNF) Therapy
Description: Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
Study: NCT03687385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygenation (HFNO)
Description: Experimental HFNO: O2 flow 40L/min, FiO2 40%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-flow nasal oxygenation (LFNO)
Description: Active comparator LFNO: O2 flow 5L/min, FiO2 40%
Study: NCT01728740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose (Glucobay, BAYG5421)
Description: Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
Study: NCT03687385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low-flow nasal oxygenation (LFNO)
Description: Active comparator LFNO: O2 flow 5L/min, FiO2 40%
Study: NCT01359007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Description: 5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
Study: NCT03965767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
Study: NCT02144129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active Whole Body Electromyostimulation
Study: NCT01107977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar yoga
Description: Iyengar yoga twice/week for 6 weeks
Study: NCT02144129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive WB-EMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WB-EMS application